ArticleFrontiers in medicine2025

Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity.

Shujuan Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.